Jubilant Ingrevia posts highest profit in 14 quarters on volume recovery
Q4 revenue rose 12% as the company navigated Middle East disruptions and commissioned a new agro CDMO plant. Management guides for sequential growth to start FY27.
— 4 earlier stories on Jubilant Ingrevia Ltd. →What's new
- Q4 revenue climbed 12% YoY to ₹1,179 cr on 10% volume growth and improved pricing.
- EBITDA grew 11% to ₹172 cr; PAT rose 17% to ₹86 cr.
- Commissioned a new agro CDMO facility and avoided production losses from Middle East supply disruptions.
Why this matters
A 14-quarter profit high is a clear signal that the volume recovery in specialty chemicals and nutrition is real, not just guidance. The new agro CDMO facility also adds capacity just as the company expects sequential growth to continue.
What we're watching
- Q1 FY27 execution against the guidance for sequential revenue and EBITDA growth.
- Momentum in the acetyls segment following the demand recovery noted by management.
- Performance of the newly commissioned agro CDMO facility.
The full read
Jubilant Ingrevia's Q4 numbers confirm a genuine recovery. Revenue of ₹1,179 crore was up 12% year-on-year, fueled by 10% volume growth and better pricing. That flow-through reached the bottom line, where net profit of ₹86 crore marked the company's best quarter in 14 quarters. The operation was also resilient: it dodged Middle East supply disruptions without downtime and added a new agro CDMO facility. Management's guidance for sequential growth into FY27 is optimistic, but it rests on a tangible base. The acetyls business is recovering, and the specialty chemicals and nutrition segments are already carrying momentum. The question is execution, not demand.
Questions answered
- How did Jubilant Ingrevia achieve its best quarterly profit in over three years?
- The result was driven by 10% volume growth and better pricing in the second half of Q4, particularly in specialty chemicals and nutrition. Revenue grew 12% to ₹1,179 cr, and the company successfully navigated Middle East supply disruptions without any production stoppages.
- What is the new capacity the company commissioned?
- Jubilant Ingrevia commissioned a new agro contract development and manufacturing (CDMO) facility during the quarter. The filing does not disclose the investment size or specific capacity added.
- What is the outlook for the next quarter?
- Management guided for sequential growth in both revenue and earnings starting Q1 FY27. It cited demand recovery in acetyls and continued momentum in specialty chemicals and nutrition as the supporting factors.
- How did the company handle supply chain issues?
- The company stated it 'successfully navigated' supply disruptions originating from the Middle East without incurring any production losses. The filing provides no further detail on the nature of the disruptions.
Jubilant Ingrevia Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on JUBLINGREA →- 26 May 2026 · 3:00 PM IST Jubilant Ingrevia posts highest profit in 14 quarters on volume recovery
- 38d ago Jubilant Ingrevia's call transcript quantifies a ₹3,500 cr CDMO pipeline
- 41d ago Jubilant Ingrevia's $300M agro client faces financial distress
- 41d ago Jubilant Ingrevia hits 14-quarter revenue high, guides for more
- 41d ago Jubilant Ingrevia's FY26 profit grows 10.6%. The numbers were expected.